Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2000-03-22
2002-11-19
Caputa, Anthony C. (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S387700, C530S388100, C530S388200, C530S388700, C530S388730, C530S388750, C530S388800, C530S388850, C530S391100, C530S391300, C530S391700, C435S002000, C435S355000, C435S372000
Reexamination Certificate
active
06482926
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to novel antibody compositions, and processes and kits for preparing enriched cell preparations, such as cell preparations enriched in human hematopoietic progenitor cells or stem cells or non-hematopoietic tumor cells.
BACKGROUND OF THE INVENTION
Blood cells have a relatively short life span and need to be replenished throughout life. In adults, blood cell formation or hematopoiesis takes place in the bone marrow, but blood-forming stem cells can also be found in peripheral blood. Hematopoietic cells represent a hierarchy of proliferating and differentiating cells. The most abundant are the differentiating or lineage committed cells. These cells have limited or no proliferative capacity and represent specialized end cells that are found in blood, and their immediate precursors.
The immediate precursors of the differentiating cells are the progenitor cells. Most of these cells are restricted to differentiate along a single lineage but they may have quite extensive proliferative capacity. Progenitor cells appear morphologically as blast cells, and they typically do not have specific features of the hematopoietic lineage to which they are committed.
Progenitor cells are derived from stem cells. Stem cells have been historically defined as cells capable of long term hematopoietic repopulation. This implies their ability to self-renew as well as to generate daughter cells of any of the hematopoietic lineages. The presence of stem and progenitor cells may be detected by their ability to produce colony-forming cells in culture and repopulate xenogeneic hosts such fetal sheep (Zanjani et al., 1994 J. Clin. Invest. Vol. 89, p. 1178-1188) and immuno-deficient mice (Dick et al., 1991 Immunological Reviews, Vol. 124:25-43). They may also be detected by screening for the CD34 antigen which is a positive marker for early hematopoietic cells including colony forming cells and stem cells. At present, the long term culture initiating cell (LTCIC) assay appears to be the best way to detect stem cells, or at least the most primitive progenitor cells, using tissue culture methodologies.
There is a continued interest in developing stem cell purification techniques. Pure populations of stem cells will facilitate studies of hematopoiesis. Transplantation of hematopoietic cells from peripheral blood and/or bone marrow is also increasingly used in combination with high-dose chemo- and/or radiotherapy for the treatment of a variety of disorders including malignant, nonmalignant and genetic disorders. Very few cells in such transplants are capable of long-term hematopoietic reconstitution, and thus there is a strong stimulus to develop techniques for purification of hematopoietic stem cells. Furthermore, serious complications and indeed the success of a transplant procedure is to a large degree dependent on the effectiveness of the procedures that are used for the removal of cells in the transplant that pose a risk to the transplant recipient. Such cells include T lymphocytes that are responsible for graft versus host disease (GVHD) in allogenic grafts, and tumor cells in autologous transplants that may cause recurrence of the malignant growth. It is also important to debulk the graft by removing unnecessary cells and thus reducing the volume of cyropreservant to be infused.
Hematopoietic cells have been separated on the basis of physical characteristics such as density and on the basis of susceptibility to certain pharmacological agents which kill cycling cells. The advent of monoclonal antibodies against cell surface antigens has greatly expanded the potential to distinguish and separate distinct cell types, There are two basic approaches to separating cell populations from bone marrow and peripheral blood using monoclonal antibodies. They differ in whether it is the desired or undesired cells which are distinguished/labeled with the antibody(s).
In positive selection techniques the desired cells are labeled with antibodies and removed from the remaining unlabeled/unwanted cells. In negative selection, the unwanted cells are labeled and removed. Antibody/complement treatment and the use of immunotoxins are negative selection techniques, but FACS sorting and most batch wise immunoadsorption techniques can be adapted to both positive and negative selection. In immunoadsorption techniques cells are selected with monoclonal antibodies and preferentially bound to a surface which can be removed from the remainder of the cells e,g. column of beads, flasks, magnetic particles. Immunoadsorption techniques have won favour clinically and in research because they maintain the high specificity of targeting cells with monoclonal antibodies, but unlike FACSorting, they can be scaled up to deal directly with the large numbers of cells in a clinical harvest and they avoid the dangers of using cytotoxic reagents such as immunotoxins, and complement.
Current positive selection techniques for the purification of hematopoietic stem cells target and isolate cells which express CD34 (approximately 1-2% of normal bone marrow) (Civin, C. L., Trischmann, T. M., Fackler, M. J., Bernstein, I. D., Buhring, H. J., Campos, L. et al. 1989 Report on the CD34 cluster workshop, In: Leucocyte typing IV, White Cell Differentiation Antigens. Knapp, W., Dorken, B., Gilks, W. R., Reiber, E. P., Schmidt, R. E., Stein, H., and Kr. von den Borne, AE.G Eds., Oxford University Press. Oxford, pp.818). Thus, the potential enrichment of hematopoietic stem cells using this marker alone is approximately 50 fold. Available techniques typically recover 30-70% of the CD34
+
cells in the start suspension and produce an enriched suspension which is 50-90% CD34
+
(Firat et al., 1988, Bone Marrow Transplantation, Vol. 21:933-938; deWynter, E. A. et al., 1975, Stem Cells, Vol. 13:524-532; Shpall, E. J., et al. 1994, J. of Clinical Oncology 12:28-36; Thomas, T. E., 1994, Cancer Research, Therapy and Control 4(2): 119-128). The positive selection procedures suffer from many disadvantages including the presence of materials such as antibodies and/or magnetic beads on the CD34
+
cells, and damage to the cells resulting from the removal of these materials. Also to be considered is the recent evidence that some long term repopulating cells are CD34
−
(negative) (Zanjani et al., 1998, Exp. Hematol., Vol. 26:353-360) and methods that isolate CD34
+
will not capture these cells.
Negative selection has been used to remove minor populations of cells from clinical grafts. These cells are either T-cells or tumor cells that pose a risk to the transplant recipient. The efficiency of these purges varies with the technique and depends on the type and number of antibodies used. Typically, the end product is very similar to the start suspension, missing only the tumor cells or T-cells.
Transplants of purified stem cells without differentiated or lineage committed cells will give short and long-term hematopoietic support (Shpall, E. J., et al. 1994, J. of Clinical Oncology 12:28-36). Since differentiated cells make up a vast majority of the cells in bone marrow and blood, depletion of these cells produces a much smaller cell suspension. The number of cells in the final product and the degree of enrichment of progenitor/stem cells will depend on the efficiency of the antibody targeting and the removal of labeled cells.
There are several studies that enrich for hematopoietic stem cells by depleting lineage committed cells but all require a number of positive or negative selection steps to achieve the desired degree of enrichment (50 fold). Early studies required prior density separation and extensive incubations to remove adherent cells (Linch, D. C, and Nathan, D. G. 1984, Nature 312 20/27: 775-777; Sieff, C. A., et al., 1985, Science 230: 1171-1173; Kannourakis, G. and Bol, S., 1987 Exp. Hematol 15:1103-1108.). More recent techniques are no less cumbersome; involving density separation steps followed by two partial lineage depletions (Winslow, J. M., et al., 1994, Bone Marrow Transplantation 1
Lansdorp Peter
Thomas Terry
Bereskin & Parr
Canella Karen A.
Caputa Anthony C.
Gravelle Micheline
StemCell Technologies Inc.
LandOfFree
Antibody compositions for preparing enriched cell preparations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody compositions for preparing enriched cell preparations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody compositions for preparing enriched cell preparations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2984465